Norges Bank’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-103,311
Closed -$332K 1932
2024
Q1
$332K Sell
103,311
-585,839
-85% -$2.27M ﹤0.01% 1858
2023
Q4
$3.38M Sell
689,150
-116,822
-14% -$533K ﹤0.01% 1735
2023
Q3
$4.39M Hold
805,972
﹤0.01% 1704
2023
Q2
$5.41M Hold
805,972
﹤0.01% 1701
2023
Q1
$7.12M Sell
805,972
-274,249
-25% -$2.42M ﹤0.01% 1672
2022
Q4
$8.25M Hold
1,080,221
﹤0.01% 1626
2022
Q3
$7.69M Sell
1,080,221
-45,454
-4% -$428K ﹤0.01% 1622
2022
Q2
$9.11M Buy
1,125,675
+60,206
+6% +$529K ﹤0.01% 1594
2022
Q1
$14.8M Buy
1,065,469
+26,846
+3% +$422K ﹤0.01% 1540
2021
Q4
$29.1M Buy
1,038,623
+68,914
+7% +$2.11M 0.01% 1256
2021
Q3
$33M Buy
969,709
+54,830
+6% +$1.98M 0.01% 1151
2021
Q2
$37.4M Buy
914,879
+245,037
+37% +$9.53M 0.01% 1136
2021
Q1
$27M Sell
669,842
-158,038
-19% -$8.55M 0.01% 1351
2020
Q4
$49M Sell
827,880
-97,881
-11% -$5.05M 0.01% 983
2020
Q3
$45M Buy
925,761
+859,492
+1,297% +$36.1M 0.01% 895
2020
Q2
$3.21M Hold
66,269
﹤0.01% 1917
2020
Q1
$1.84M Buy
66,269
+50,000
+307% +$1.39M ﹤0.01% 1930
2019
Q4
$487K Sell
16,269
-28,731
-64% -$825K ﹤0.01% 2053
2019
Q3
$1.39M Hold
45,000
﹤0.01% 2018
2019
Q2
$2.17M Buy
+45,000
New +$1.99M ﹤0.01% 1993

Other funds holding ADPT

Norges Bank's ADPT Position: Q2 2024 in Review

Norges Bank sold out of Adaptive Biotechnologies (ADPT) in Q2 2024, closing a stake of 103,311 shares — an estimated $332K sold.

Norges Bank first reported a position in ADPT in Q2 2019 and held it in 20 quarters. The position peaked at $49M in Q4 2020. 176 funds tracked by Wall St. Rank hold ADPT as of Q2 2024.

  • Norges Bank reported no remaining Adaptive Biotechnologies position as of Q2 2024 after selling out during the quarter.
  • Norges Bank sold 103,311 Adaptive Biotechnologies shares in Q2 2024, an estimated $332K.
  • Norges Bank first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 20 quarters.
  • Norges Bank's Adaptive Biotechnologies position peaked at $49M in Q4 2020.
  • 176 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2024.

Based on Norges Bank's 13F filing for Q2 2024, filed 14 Aug 2024.